We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Insights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma

Source: Pharmacy Times articles The combination yields promising results but was associated with high incidence of toxicity and infection. Read More

Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More

IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab

Source: Pharmacy Times articles For patients with multiple myeloma who may experience an infection while receiving teclistamab, supplementation with intravenous immunoglobulin (IVIG) can help resolve and prevent serious complications. Read More

Recent Publications

Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes

Ann Hematol. 2024 Dec;103(12):5849-5859. doi: 10.1007/s00277-024-06129-5. Epub 2024 Dec 7....

Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials

Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):32-44. doi: 10.1016/j.clml.2024.09.008. Epub 2024 Sep...

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma

Front Immunol. 2024 Dec 23;15:1466443. doi: 10.3389/fimmu.2024.1466443. eCollection 2024. ABSTRACT...

Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses

J Oncol Pharm Pract. 2024 Nov 21:10781552241290452. doi: 10.1177/10781552241290452. Online ahead...

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia

Heliyon. 2024 Oct 22;10(21):e39698. doi: 10.1016/j.heliyon.2024.e39698. eCollection 2024 Nov 15....

Email

info@myeloma360.com